Farxiga significantly reduced the worsening of renal function or risk of death in patients with chronic kidney disease with and without type-2 diabetes

Attachments

  • Original document
  • Permalink

Disclaimer

AstraZeneca plc published this content on 28 July 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 July 2020 06:10:09 UTC